GOLDSTEIN JOSEPH L 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Feb 8, 2023
Insider Transaction Report
Form 4
GOLDSTEIN JOSEPH L
Director
Transactions
- Exercise/Conversion
Common Stock
2023-02-06$482.68/sh+3,613$1,743,923→ 9,860 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2023-02-06−3,613→ 0 totalExercise: $482.68Exp: 2031-01-04→ Common Stock (3,613 underlying) - Sale
Common Stock
2023-02-06$800.00/sh−3,613$2,890,400→ 6,247 total
Footnotes (2)
- [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- [F2]On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.